U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H32N6O2
Molecular Weight 520.6248
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PURMORPHAMINE

SMILES

C1CCC(CC1)N2C=NC3=C(NC4=CC=C(C=C4)N5CCOCC5)N=C(OC6=CC=CC7=C6C=CC=C7)N=C23

InChI

InChIKey=FYBHCRQFSFYWPY-UHFFFAOYSA-N
InChI=1S/C31H32N6O2/c1-2-9-25(10-3-1)37-21-32-28-29(33-23-13-15-24(16-14-23)36-17-19-38-20-18-36)34-31(35-30(28)37)39-27-12-6-8-22-7-4-5-11-26(22)27/h4-8,11-16,21,25H,1-3,9-10,17-20H2,(H,33,34,35)

HIDE SMILES / InChI

Molecular Formula C31H32N6O2
Molecular Weight 520.6248
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15380183 | https://www.ncbi.nlm.nih.gov/pubmed/21979788 | https://www.ncbi.nlm.nih.gov/pubmed/25341035

Purmorphamine is agonist of the protein Smoothened, a key part of the hedgehog signaling pathway, which is involved in bone growth and brain development as well as having a number of other functions in the body. Purmorphamine induces osteogenesis in multipotent mesenchymal progenitor cells. It demonstated neuroprotective action in mouse model of brain ischemia and cytoprotective effect in cellular model of amyotrophic lateral sclerosis.

Originator

Curator's Comment: The first article was co-authored by The Scripps Research Institute and Genomics Institute of the Novartis Research Foundation. The Scripps Research Institute was applicant of the first patent on purmorphamine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Focal ischemia was induced by permanent occlusion of the left middle cerebral artery (MCA) under isoflurane anesthesia. Briefly, a skin incision was made between the orbit and the ear. Under an operating microscope, the temporal muscle was divided to locate the distal course of the left MCA through the translucent skull. A small burr-hole craniotomy was performed with a microdrill and the exposed MCA was coagulated using a bipolar pencil. Permanent occlusion was ensured by physical division. Animals were randomly divided into groups and received a single dose of 1, 5 and 15 mg/kg of purmorphamine (PUR) or VEH (PEG-400: ethanol: water (40 : 20 : 40) i.v. or i.p. at 6 h after MCAO. SHAM-operated animals were injected with VEH. CyP (10 mg/kg) was administered 40 min before PUR.
Route of Administration: Other
Smo binding assays were conducted with BODIPY-cyclopamine and Smo-overexpressing cells using CMV promoter-based, SV40 origin-containing expression constructs for Smo-Myc3, the deletion mutant Smo.Delta.CRD (deletion of amino acids 68 to 182), and Smo.Delta.CT (deletion of amino acids 556 to 793). HEK 293T cells were grown on poly-D-lysine-treated glass coverslips in 12-well plates until 70% confluency and then transfected with the appropriate expression construct (0.5 ug/well) using FuGene 6 according the manufacturer’s protocols. Two days after transfection, the HEK 293T cells were incubated with DMEM containing 0.5% bovine calf serum, 5 nM BODIPY-cyclopamine, and varying concentrations of purmorphamine (0, 1.5, or 5 uM) (1 mL/well) for 1 h at 37 °C. The Smo-overexpressing cells were then washed with 1X PBS buffer (1 mL/well), mounted with DAPI-containing medium, and visualized using a Leica DM4500B fluorescence microscope. For binding assays using fixed cells, the Smo-overexpressing HEK 293T cells were fixed with 3% paraformaldehyde in 1X PBS buffer for 10 min at room temperature (1 mL/well), treated with 1X PBS containing 10 mM glycine and 0.2% sodium azide for 5 min (1 mL/well), washed with 1X PBS buffer (1 mL/well), and treated with the compound-containing media described above for 4 h at room temperature.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:59:46 UTC 2023
Edited
by admin
on Sat Dec 16 10:59:46 UTC 2023
Record UNII
PB12M2F8KY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PURMORPHAMINE
MI  
Common Name English
9H-PURIN-6-AMINE, 9-CYCLOHEXYL-N-(4-(4-MORPHOLINYL)PHENYL)-2-(1-NAPHTHALENYLOXY)-
Systematic Name English
9-CYCLOHEXYL-N-(4-(4-MORPHOLINYL)PHENYL)-2-(1-NAPHTHALENYLOXY)-9H-PURIN-6-AMINE
Systematic Name English
PURMORPHAMINE [MI]
Common Name English
Code System Code Type Description
MERCK INDEX
m9323
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY Merck Index
FDA UNII
PB12M2F8KY
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY
WIKIPEDIA
Purmorphamine
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY
EPA CompTox
DTXSID20415293
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY
PUBCHEM
5284329
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY
CAS
483367-10-8
Created by admin on Sat Dec 16 10:59:46 UTC 2023 , Edited by admin on Sat Dec 16 10:59:46 UTC 2023
PRIMARY